Full source list

You can check all list sources of THYBLATE™ RFA Solutions.

Sources

  • www.thyroid.org
  • Haugen, Bryan R et al. “2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.” Thyroid : official journal of the American Thyroid Association vol. 26,1 (2016): 1-133. doi:10.1089/thy.2015.0020
  • Kim, Ji-Hoon et al. “2017 Thyroid Radiofrequency Ablation Guideline: Korean Society of Thyroid Radiology.” Korean journal of radiology vol. 19,4 (2018): 632-655. doi:10.3348/kjr.2018.19.4.632
  • Orloff, Lisa A et al. “Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary consensus statement of the American Head and Neck Society Endocrine Surgery Section with the Asia Pacific Society of Thyroid Surgery, Associazione Medici Endocrinologi, British Association of Endocrine and Thyroid Surgeons, European Thyroid Association, Italian Society of Endocrine Surgery Units, Korean Society of Thyroid Radiology, Latin American Thyroid Society, and Thyroid Nodules Therapies Association.” Head & neck vol. 44,3 (2022): 633-660. doi:10.1002/hed.26960
  • Seo YK, Cho SW, Sim JS, Yang GE, Cho W.   Radiofrequency Ablation of Papillary Thyroid Microcarcinoma: A 10-Year Follow-Up Study.   J Korean Soc Radiol. 2021 Jul;82(4):914-922.   https://doi.org/10.3348/jksr.2020.0128
  • Papini, Enrico et al. “2020 European Thyroid Association Clinical Practice Guideline for the Use of Image-Guided Ablation in Benign Thyroid Nodules.” European thyroid journal vol. 9,4 (2020): 172-185. doi:10.1159/000508484
  • Ha, Eun Ju et al. “Radiofrequency ablation of benign thyroid nodules: recommendations from the Asian Conference on Tumor Ablation Task Force.” Ultrasonography (Seoul, Korea) vol. 40,1 (2021): 75-82. doi:10.14366/usg.20112
  • Tufano, Ralph P et al. “Update of Radiofrequency Ablation for Treating Benign and Malignant Thyroid Nodules. The Future Is Now.” Frontiers in endocrinology vol. 12 698689. 24 Jun. 2021, doi:10.3389/fendo.2021.698689
  • Jung, So Lyung et al. “Efficacy and Safety of Radiofrequency Ablation for Benign Thyroid Nodules: A Prospective Multicenter Study.” Korean journal of radiology vol. 19,1 (2018): 167-174. doi:10.3348/kjr.2018.19.1.167
  • Chung, Sae Rom et al. “Safety of radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: a systematic review and meta-analysis.” International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group vol. 33,8 (2017): 920-930. doi:10.1080/02656736.2017.1337936
  • Mauri, Giovanni et al. “Minimally-invasive treatments for benign thyroid nodules: recommendations for information to patients and referring physicians by the Italian Minimally-Invasive Treatments of the Thyroid group.” Endocrine vol. 76,1 (2022): 1-8. doi:10.1007/s12020-022-03005-y
  • Valcavi, Roberto, and Petros Tsamatropoulos. “HEALTH-RELATED QUALITY OF LIFE AFTER PERCUTANEOUS RADIOFREQUENCY ABLATION OF COLD, SOLID, BENIGN THYROID NODULES: A 2-YEAR FOLLOW-UP STUDY IN 40 PATIENTS.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists vol. 21,8 (2015): 887-96. doi:10.4158/EP15676.OR

INDICATIONS FOR USE & IMPORTANT SAFETY INFORMATION

The THYBLATE™ electrodes are CE-certified and indicated for the treatment of benign thyroid nodules (cystic and non-cystic), goiters, AFTN, and malignant tumors. The THYBLATE™ electrodes are FDA 510(k) cleared for percutaneous and intraoperative coagulation and ablation of tissue. While the THYBLATE™ Thyroid RFA Procedure may offer substantial benefits to many patients, it is not universally applicable, and individual outcomes may vary. Please contact your medical professional for specific advice regarding the potential benefits, risks, and suitability of this treatment in your specific case.

LEGAL DISCLAIMER

The Site cannot and does not provide medical/health advice. The medical/health information here is for general informational and educational purposes only and is not a substitute for professional advice. The content on this Site is not intended for sale or promotion in jurisdictions where such activities are restricted. The imagery used on this Site is for illustrative purposes only and should not be interpreted as an endorsement or representation of typical patient outcomes. For more details about the information provided on this Site, please click here.

FULL SOURCE LIST

To find the full list of sources used on this website, please click here.